Division of Hematology, Department of Medicine, Oncology and Cell Therapy, Rush University Medical Center, Chicago, Illinois, USA.
Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Oncologist. 2021 Apr;26(4):263-265. doi: 10.1002/onco.13634. Epub 2020 Dec 24.
Osimertinib, a third‐generation EGFR tyrosine kinase inhibitor (TKI), is the new first line standard of care in metastatic non‐small cell lung cancer (NSCLC) based on improvements in overall survival (OS), control of central nervous system (CNS) disease, and a superior toxicity profile. This commentary highlights interim results from the ADAURA trial, continuing the effort to establish a role for EGFR TKIs in the adjuvant setting.
奥希替尼是第三代表皮生长因子受体酪氨酸激酶抑制剂（TKI），基于其在总生存期（OS）、中枢神经系统（CNS）疾病控制和更优毒性特征方面的改善，它是转移性非小细胞肺癌（NSCLC）新的一线标准治疗药物。这篇评论重点介绍了 ADAURA 试验的中期结果，该试验继续致力于确定 EGFR TKI 在辅助治疗中的作用。
